From syncope to ICD: clinical paths of the Brugada syndrome


Submitted: 15 February 2013
Accepted: 15 February 2013
Published: 18 September 2010
Abstract Views: 870
PDF: 3078
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Ivan Comelli Dipartimento di Scienze Cliniche e Scuola di Specializzazione in Medicina di Emergenza-Urgenza, Università degli Studi, Parma, .
  • Gianfranco Cervellin UO Pronto Soccorso e Medicina d’Urgenza, Azienda Ospedaliero-Universitaria, Parma, .
  • Tiziana Meschi Dipartimento di Scienze Cliniche e Scuola di Specializzazione in Medicina di Emergenza-Urgenza, Università degli Studi, Parma., .
  • Loris Borghi Dipartimento di Scienze Cliniche e Scuola di Specializzazione in Medicina di Emergenza-Urgenza, Università degli Studi, Parma., .
This review summarizes the evidences in the literature on the management of the Brugada syndrome (BS), an arrhythmogenic disease caused by genetic channelopathies, predisposing to syncope and sudden cardiac death in young, apparently healthy, typically male subjects, in the third and fourth decade of their life. Sudden cardiac death (SCD) is defined as natural death from cardiac causes, heralded by abrupt loss of consciousness within one hour of the onset of symptoms. It ranks among the main causes of death in the western world, with an incidence ranging from 0.36 and 1.28‰ inhabitants per year, equal to 300,000 cases a year in the USA. In the majority of the cases it is due to the onset of arrhythmia in subjects with structural cardiac diseases, especially ischemic heart disease. However, in a non-negligible percentage of the cases, about 5-10%, the SCD arises in relatively young individuals in whom cardiac anomalies cannot be detected using traditional diagnostic techniques. About 20% of these cases can be attributed to SB. In spite of the many efforts produced to identify an effective pharmacological treatment, to date the only aid to reduce the mortality rate in subjects with SB is an implantable cardio-defibrillator (ICD). Since this approach often entails complications, the efforts of the scientific community is now focused on the assessment of the arrhythmic risk. The identification of high-risk subjects is one of the chief objectives in the therapeutic decision-making process. ABSTRACT clinica e terapia emergency

Comelli, I., Cervellin, G., Meschi, T., & Borghi, L. (2010). From syncope to ICD: clinical paths of the Brugada syndrome. Emergency Care Journal, 6(3), 7–14. https://doi.org/10.4081/ecj.2010.3.7

Downloads

Download data is not yet available.

Citations